Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients

Stefano Di Bella, Theodore Gouliouris, Nicola Petrosillo

Research output: Contribution to journalArticlepeer-review


Clostridium difficile infection (CDI) is an emerging problem worldwide associated with significant morbidity, mortality, recurrence rates and healthcare costs. Immunosuppressed patients, including HIV-seropositive individuals, solid organ transplant recipients, patients with malignancies, hematopoietic stem cell transplant recipients, and patients with inflammatory bowel disease are increasingly recognized as being at higher risk of developing CDI where it may be associated with significant complications, recurrence, and mortality. Fecal microbiota transplantation (FMT) has proven to be an effective and safe procedure for the treatment of recurrent or refractory CDI in immunocompetent patients by restoring the gut microbiota and resistance to further recurrences. During the last two years the first data on FMT in immunocompromised patients began to appear in the medical literature. Herein we summarize the use of FMT for the treatment of CDI with a focus on immunocompromised patients.

Original languageEnglish
Pages (from-to)230-237
Number of pages8
JournalJournal of Infection and Chemotherapy
Issue number4
Publication statusPublished - Apr 1 2015


  • Clostridium difficile
  • Fecal microbiota transplantation
  • FMT
  • Immunocompromised
  • Microbiota

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients'. Together they form a unique fingerprint.

Cite this